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Abstract
Background: Birt-Hogg-Dube´ syndrome (BHD) is a rare autosomal dominant disorder characterised by the occurrence of
benign, mostly facial, skin tumours called fibrofolliculomas, multiple lung cysts, spontaneous pneumothorax and an
increased renal cancer risk. Current treatments for fibrofolliculomas have high rates of recurrence and carry a risk of
complications. It would be desirable to have a treatment that could prevent fibrofolliculomas from growing. Animal models
of BHD have previously shown deregulation of mammalian target of rapamycin (mTOR). Topical use of the mTOR inhibitor
rapamycin is an effective treatment for the skin tumours (angiofibromas) in tuberous sclerosis complex, which is also
characterised by mTOR deregulation. In this study we aimed to determine if topical rapamycin is also an effective treatment
for fibrofolliculomas in BHD.
Methods: We performed a double blinded, randomised, facial left-right controlled trial of topical rapamycin 0.1% versus
placebo in 19 BHD patients. Trial duration was 6 months. The primary outcome was cosmetic improvement as measured by
doctors and patients. Changes in fibrofolliculoma number and size were also measured, as was occurrence of side effects.
Results: No change in cosmetic status of fibrofolliculomas was reported in the majority of cases for the rapamycin treated
(79% by doctors, 53% by patients) as well as the placebo treated facial sides (both 74%). No significant differences between
rapamycin and placebo treated facial halves were observed (p = 1.000 for doctors opinion, p = 0.344 for patients opinion).
No significant difference in fibrofolliculoma number or change in size of the fibrofolliculomas was seen after 6 months. Side
effects occurred more often after rapamycin treatment (68% of patients) than after placebo (58% of patients; p = 0.625). A
burning sensation, erythema, itching and dryness were most frequently reported.
Conclusions: This study provides no evidence that treatment of fibrofolliculomas with topical rapamycin in BHD results in
cosmetic improvement.
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Introduction
Birt-Hogg-Dube´ syndrome (BHD, MIM #135150) was first
described in 1975 by Hornstein and Knickenberg and again in
1977 by Birt, Hogg and Dube´ [1,2]. It is a rare autosomal
dominant disorder characterized by the occurrence of benign,
mostly facial, hair follicle tumours called fibrofolliculomas (FF)s
[2], multiple lung cysts, spontaneous pneumothorax [3], and an
increased renal cancer risk [4–6]. The FFs can be quite disfiguring
and are often the reason why patients come to medical attention.
FFs occur in around 80% of patients and usually appear after the
age of 20 years as dome-shaped, whitish or skin-coloured papules.
Typically presenting around the nose, they can also occur on the
ears, neck and trunk [2]. Although they do not grow beyond 3–
4 mm in size, their numbers increase with age. Consequently,
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patients can eventually have hundreds of papules that may cause
emotional distress and have a strong impact on their quality of life.
Current treatment options for FFs include destructive ap-
proaches such as ablative laser, electrocoagulation, excision and
other invasive interventions [7–10]. These treatments have high
recurrence rates (for laser therapy it is known that FFs recur after
2–3 years or even after months [9]) and are not effective in
preventing early lesions. Moreover, they have a significant risk of
complications such as scarring, inflammation, hypo- and hyper-
pigmentation. Therefore, there is a medical need for a more
targeted therapy that is suitable for chronic use, reduces the
number of tumours and/or prevents the growth of new ones.
Insights from genetic and cell biological studies have suggested
such an approach.
BHD syndrome is caused by germline mutations in the FLCN
gene on chromosome 17p11.2 coding for the protein folliculin
(FLCN) [11,12]. FLCN’s functions are mostly unknown, although
recent data suggest that it might be involved in cellular energy
sensing through the mammalian target of rapamycin (mTOR)
signalling pathway [13]. A considerable body of data suggests that
in BHD, the mTOR pathway is activated [14–18]. Thus, we
theorized that BHD syndrome belongs to a larger family of
disorders characterized by mTOR deregulation, such as tuberous
sclerosis complex (TSC) [14,19]. In yeast, the homologue of FLCN
is found to have opposing roles to the genes involved in TSC
(TSC1 and TSC2), but all are suggested to regulate common
downstream targets [20]. In TSC, as in BHD, patients develop
facial hair follicle tumours, called angiofibromas. These tumours
strongly resemble FFs and have also been reported in BHD
syndrome (Figure 1) [21,22]. Angiofibromas in TSC were
coincidentally found to respond favourably to the mTOR inhibitor
rapamycin. They disappeared after only a few months of oral
rapamycin, which was administered after renal transplantation
[23]. Oral administration of rapamycin has potential side effects
that are not acceptable in the context of BHD. However, there are
several studies showing that topical application is safe [24–26].
Additionally, multiple reports show successful treatment of
angiofibromas in TSC with topical rapamycin [24,26–30]. Thus,
we hypothesized that rapamycin oral solution might be used for
the topical treatment of FFs.
We here show the results of the first double-blind placebo-
controlled randomized split-face trial of topical rapamycin for the
treatment of FFs in BHD. The objective of this study was to
determine whether topical application of rapamycin 1 mg/ml oral
solution could lead to overall cosmetic improvement and reduction
in size and number of facial FFs in BHD patients. Secondly, we
evaluated safety and formula acceptance.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information (Protocol S1 & Checklist
S1). Before patient recruitment started the study was deposited at
ClinicalTrials.gov (NCT00928798; http://www.clinicaltrials.gov/
ct2/show/NCT00928798?term= rapamycin+BHD&rank= 1).
Ethics Statement
This study was approved by the Medical Ethical Committees of
the Maastricht University Medical Centre+ and the VU Medical
Centre Amsterdam, Licence number NL28245.068.09 and was
conducted in accordance with the Helsinki Declaration of 1975.
The individuals shown in this manuscript have given written
informed consent (as outlined in PLOS consent form) to publish
their pictures.
Patients
Patient recruitment, inclusion and follow-up occurred at the
Department of Dermatology in the Maastricht University Medical
Centre+ and at the Department of Clinical Genetics in the VU
Medical Centre Amsterdam, both reference centres for patients
with BHD. Patients with genetically proven BHD, a minimum age
of 18 years, at least 10 facial FFs (of which at least one
histologically confirmed) and a general good health were eligible
for inclusion. Pregnant or lactating women, patients with proven
or suspected skin or other malignancy in the past 5 years and
patients who planned facial surgery in the treatment period were
excluded. Because of the increased risk of renal cell carcinoma in
BHD patients, screening by an abdominal ultrasound or MRI was
scheduled for patients who had their last screening more than 1
year ago. Patients with concomitant disease requiring systemic
immunosuppressive treatment and patients using any facial topical
immunosuppressive treatment or facial topical drugs interfering
with rapamycin during the trial period or within 30 days before
starting therapy were excluded, as were patients with facial skin
lesions other than FFs that might worsen under rapamycin, such as
active infections. Next to these protocolled criteria, patients were
excluded when they could not attend any of the follow-up visits,
because this made monitoring of (side) effects and adverse events
impossible. A biopsy of a facial FF was taken if this had not been
performed earlier. Written informed consent was obtained from all
patients eligible for participation.
Treatment procedures
Computer generated randomisation was performed using
random permuted blocks of 2. Randomisation was stratified by
participating centres. For each participant, topical treatment with
a commercially available rapamycin (sirolimus) oral solution
1 mg/ml was randomized to one facial half and application of a
placebo solution to the other facial half. Patients were instructed to
topically apply the two formulations twice daily, for 6 months. The
rapamycin solution was decanted at 2–8uC in a nitrogen
atmosphere and packaged in amber glass bottles to preserve
solution quality. The solvent was used as a placebo and was
packaged in identical bottles. Bottles were numbered and marked
‘left’ or ‘right’ by the pharmacist, in order to conceal randomisa-
tion. Patients and investigator were both blinded for the treatment
of each facial side throughout the study.
Efficacy assessment
Patients were clinically assessed at baseline, 3 months and 6
months by a single investigator (LMCG). Evaluation consisted of
careful examination of the face, including assessment of facial FF
Figure 1. Skin features in TSC and BHD. Photographs taken from a
TSC and a BHD patient show angiofibromas and fibrofolliculomas,
respectively. Notice the resemblance between the two types of lesion.
doi:10.1371/journal.pone.0099071.g001
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number and size, as well as the change in general cosmetic FF
status compared to baseline. At each visit, facial medical
photographs were obtained under standardized conditions con-
cerning: studio lighting, subject positions, predetermined camera
settings (distance to subject, resolution, aperture settings, exposure
time) and background. For each patient full front, left and right
oblique views (45u) and left and right profile views (90u) were
obtained. Photographs were evaluated twice by 3 physicians; the
investigator and 2 dermatologists. All were blinded for the
treatment. They assessed the size of the largest FF in a predefined
area. Right and left facial halves were scored separately and 3-
month and 6-month photographs were compared to baseline. The
change in general cosmetic FF status was evaluated using a 7-point
Likert scale (23= strong worsening; 22= moderate worsening;
21= minimal worsening; 0= no change; 1= minimal improve-
ment; 2 = moderate improvement; 3 = strong improvement)
[31,32]. The FF number was registered in categories, (0; 1–10;11–
20;21–30; 31–40; 41–50; .50). Each of the three observers scored
the photographs twice for cosmetic status, FF size and FF number.
From the six Likert scores or categories obtained per patient the
most frequently assigned score was used for analysis. When
multiple scores were obtained in equal amounts, the score
indicating the least improvement was used. The change in FF
number was obtained by comparing the 6-month results to
baseline results. Reduction of FF number was defined as a
decrease of at least one category. Patients’ impressions concerning
cosmetic FF status were assessed as well, also using the 7-point
Likert scale. At follow-up visits we assessed and registered side
effects.
Statistical analysis
A minimum of 17 patients was needed to detect an increase in
preference for rapamycin over placebo by at least 35% (from 50%
to 85%), with a power of 90% and a type 1 error (2 sided) of 0.05.
A minimum of 35% difference in response was considered to be
clinically relevant, as a smaller difference does not justify the
routine treatment of BHD patients with rapamycin. The
McNemar’s chi-square test was used to test for discrepancies in
response to rapamycin and placebo treatment concerning cosmetic
improvement and reduction in FF number. This test was also used
to compare the proportion of side effects occurring between the
two facial sides. Differences in FF size were tested for significance
using the T-test for paired samples. A p-value smaller than 0.05
was considered to indicate statistical significance in all analyses.
The inter-observer variation of scores on cosmetic status, FF size
and number was measured using the intraclass correlation
coefficient. For data analysis we used SPSS Statistics version
20.0.0.1 (IBM, Armonk, NY, USA) and for calculation of 95%
confidence intervals (95%CI) for difference in paired proportions
we used R package ExactCIdiff version 2.15.1 (http://cran.r-
project.org/web/packages/ExactCIdiff/index.html).
Results
Study population
Between January 2010 and August 2010, 24 patients with BHD
were recruited and assessed for eligibility to participate (Figure 2).
One patient was excluded due to excessive use of alcohol and three
because of frequent travelling abroad, which made follow-up
impossible. After screening, but before randomisation, one person
had to be excluded due to the diagnosis of a malignancy not
related to BHD. A total of 19 individuals were randomised. The
distribution of baseline characteristics of the study population is
shown in table 1. One individual was not able to attend the 3-
month follow-up visit due to immobility after back surgery, but
could be evaluated at six months. This person was excluded from
the data analysis of the 3-month results (n = 18). After two months
of treatment, one patient had to discontinue the treatment because
of a tearing eye. This patient was seen at the 3-month follow-up
visit, but was considered lost to follow-up at six months. A second
patient was lost to follow-up at six months due to travelling. For
both, the 3-month data were carried forward in the 6-month
efficacy analysis (n = 19). An additional analysis of the 6-month
results was performed in which all persons that were lost to follow-
up at six months were excluded from the analysis (n = 17).
Effects of rapamycin treatment
The effect of rapamycin was assessed by measuring changes in
cosmetic status, number and size of the FFs.
Cosmetic improvement of the FFs as judged by doctors and
patients is presented in figures 3 and 4. There were no significant
Figure 2. Trial outline. * The patient who was lost to follow-up at 3
months was excluded from the analysis of the 3 month results. ** For
the patients who were lost to follow-up at 6 months, the 3-month data
were carried forward in the analysis of the 6-month results.
doi:10.1371/journal.pone.0099071.g002
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differences between rapamycin and placebo treated facial sides.
According to doctors’ opinion, improvement of cosmetic status
was seen in 10.5% of rapamycin treated facial halves and in 10.5%
of the placebo treated sides. The difference is 0% with a 95%CI of
-19% to +19%; p= 1.000 (Appendix S1). Patients reported
cosmetic improvement upon rapamycin treatment more often
than upon placebo treatment (47.3% versus 26.3%). The
difference is 21% with a 95%CI of 214% to +51%; p= 0.344
(Appendix S1).
Both doctors and patients reported no changes in the majority
of cases for the rapamycin treated (79% and 53% respectively) as
well as the placebo treated facial sides (both 74%). The doctors
reported minimal worsening in 16% of the placebo treated versus
11% of the rapamycin treated facial halves, whereas minimal
Table 1. Baseline characteristics of included patients.
Characteristic Number of patients (n =19)
Gender Male 13
Female 6
Mean age, years (range) 52 (34–70)
Number of facial fibrofolliculomas 20–50 4
50–100 4
.100 11
FLCN mutation c.319_320delGTinsCAC 1
c.610_611delGCinsTA 9
c.655dupC 1
c.1177-2A.G 1
c.1285dupC 3
c.1408_1418del 1
c.871+3_c.871+4delGAinsTCCAGAT 1
c.880G.T 1
c.250-?_1740+?del 1
Previous treatment None 15
Laser 4
Surgical 1
doi:10.1371/journal.pone.0099071.t001
Figure 3. Photographic recording of cosmetic status during rapamycin treatment. Close up of standardised facial photographs taken at
baseline, 3 months and 6 months after starting treatment with topical rapamycin or placebo per facial half. Photos of a representative patient are
shown, revealing no visible improvement or worsening of the facial fibrofolliculomas.
doi:10.1371/journal.pone.0099071.g003
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improvement was observed in 11% of both rapamycin and
placebo treated facial sides (Figure 4). Patients reported improve-
ment more frequently for the rapamycin treated compared to the
placebo treated facial side. Nine patients (47%) reported minimal
to strong improvement of the rapamycin treated facial half, versus
five (26%) reporting improvement of the placebo treated half
(Figure 4). Additional analysis of the 17 patients that were seen at
the 6-month follow-up showed similar results for the doctors’
opinion on cosmetic improvement of FFs after treatment.
Reduction in FF number was observed in 32% of rapamycin
treated sides versus 37% of placebo treated sides, with a difference
of 5% with a 95%CI of 220% to +31%; p= 1.000 (Figure 5 and
Appendix S1)
After three months of treatment the mean change in FF size was
0.054 mm on the rapamycin treated sides and 0.027 mm on the
placebo treated sides, with a mean difference of 0.027 mm with a
95%CI of 2210 to +0.264 mm; p= 0.184 (Table 2).
The inter-observer variations, expressed as intraclass correlation
coefficients (ICC) for cosmetic status, FF number and FF size are
shown in Table 3.
Side effects of topical rapamycin
The majority of patients reported one or more side effects
during the six months of treatment for rapamycin (68%) as well as
for placebo (58%) (difference 10% with 95%CI 214.3 to 35.0;
p = 0.625). A burning sensation, erythema, dryness and itching
were most frequently reported (Figure 6). Other side effects were
tearing and prickling eyes, scaling, moderate pain and a prickling
sensation of the skin. Most side effects occurred in the first three
weeks of treatment and resolved over time, with 71% reported at
the 3-month follow-up visit and only 42% at the 6-month visit. No
serious adverse events have occurred during treatment.
Discussion
This is the first randomised controlled trial in which the
effectiveness of rapamycin on persistence and growth of FFs in
patients with BHD was studied. We provide evidence that topical
rapamycin does not improve the cosmetic status of FFs in these
patients and does not reduce the amount or size of the FFs.
Previous studies in rodent and Drosophila models have suggested
a role for increased mTOR activity in the pathogenesis of BHD,
prompting this study [15–17,33]. However, other mouse models
subsequently showed conflicting data concerning the nature of the
link between FLCN and mTOR. In contrast to other studies,
Hudon et al. and Hartman et al. found decreased mTOR activity
in mice [15–17,34,35]. In human BHD tumours, the role of
Figure 4. Changes in cosmetic status of fibrofolliculomas after treatment with rapamycin scored by doctors and patients. BHD
patients with facial fibrofolliculomas were treated with topical rapamycin and placebo for six months. The degree of improvement compared to
baseline was scored on a 7-point Likert scale by both doctors (A) and patients (B). Doctors and patients reported no change in the majority of cases.
Patients reported improvement more frequently for the rapamycin compared to the placebo treated facial side.
doi:10.1371/journal.pone.0099071.g004
Figure 5. Changes in the number of fibrofolliculomas after
treatment with rapamycin. BHD patients with facial fibrofolliculo-
mas were treated with topical rapamycin and placebo for six months.
The number of fibrofolliculomas in a predefined area of the face was
determined and compared to baseline. The reduction in the number of
fibrofolliculomas was stronger upon placebo treatment.
doi:10.1371/journal.pone.0099071.g005
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mTOR had also been questioned by Claessens et al. based on
immunohistochemical assessment of BHD patient skin and kidney
tumour tissue [36]. More recent in vitro studies using FLCN
knockdown cells have not been able to confirm a direct link
between FLCN and mTOR [37] (and unpublished data). The
deregulation of mTOR activity found in the tumours of BHD
animal models could be due to mTOR’s general involvement in
cancerous growth rather than a direct effect of FLCN’s absence.
Of note, most animal models involve knockout of FLCN. FFs do
not have loss of FLCN and we have recently provided evidence that
BHD-associated kidney tumours do not have complete loss of
FLCN either [38–40]. Thus, the present state of the art suggests
that there is no clear-cut relation between FLCN and mTOR. Our
trial data support this assertion and we suggest that mTOR does
not play an active role in the maintenance or growth of
fibrofolliculomas, in contrast to angiofibromas in TSC.
We have considered alternative explanations for the observed
lack of efficacy. Firstly, the concentration of rapamycin in the
lotion might have been too low. However, the oral rapamycin
solution that we used in this study has been shown to be an
effective topical treatment for angiofibromas in TSC, without
detectable levels of rapamycin in the serum [26]. A 1:1 mixture of
rapamycin solution 1 mg/ml in an emollient has also shown to be
effective in TSC [27]. This indicates that rapamycin in this oral
solution penetrates into the skin and that the concentration of
rapamycin we used is sufficient to cause a clinical effect. Propylene
glycol is part of the solvent of the oral rapamycin and is known to
enhance topical drug delivery [41–44]. Secondly, patient compli-
Table 2. Between-treatment comparison of mean change in fibrofolliculoma size compared to baseline (in mm) using the T-test
for paired samples.
Rapamycin Placebo Difference 95% CI p-value
At 3 months 0.054 (SD 0.34) 0.027 (SD 0.27) 0,027 20,21–+0,26 0.814
At 6 months 0.100 (SD 0.29) 0.096 (SD 0.32) 0.004 20,16–+0,17 0.961
SD= standard deviation; CI = confidence interval.
doi:10.1371/journal.pone.0099071.t002
Table 3. The inter-observer variation of scores used to measure the effect of rapamycin using the intraclass correlation coefficient
(ICC).
Outcome measure Lowest ICC (95%CI) Highest ICC (95%CI)
Cosmetic status of fibrofolliculomas 0.517 (0.244–0.758) 0.633 (0.390–0.821)
Number of fibrofolliculomas 0.643 (0.324–0.840) 0.878 (0.757–0.947)
Size of fibrofolliculomas 0.374 (0.075–0.660) 0.653 (0.401–0.834)
95%IC = 95% confidence interval.
doi:10.1371/journal.pone.0099071.t003
Figure 6. Local side effects of topical rapamycin treatment. Side effects of both topical rapamycin and placebo treatment were registered at
each clinical assessment. Burning, erythema, dryness and itching were the most commonly reported local side effects. All side effects other than
dryness and itching were reported more frequently for the rapamycin treated facial half.
doi:10.1371/journal.pone.0099071.g006
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ance might have been too low. To measure compliance we
planned to weigh the used bottles with rapamycin and placebo
solution at every follow-up visit. Because the treated surface varied
widely between patients and not all bottles were retrieved,
compliance could not be determined in this way. No patient
reported to have deviated from the treatment protocol, but we
cannot rule out non-compliance. However, as most patients
experienced one or more side effects, we are confident that they
did indeed adhere to protocol. Thirdly, there was moderate
variation between the doctors in scoring the change in cosmetic
status and the size of FFs. Small random errors in classification of
cosmetic status theoretically may result in obscuring an effect of
rapamycin. However, it seems improbable that large, clinically
relevant differences would be missed by lack of perfect agreement.
Moreover, ICCs up to 0.878 were obtained for observer
agreement on FF number. For this outcome measure the results
clearly show no advantage of rapamycin treatment compared to
placebo treatment.
In this randomised controlled trial both doctors’ and patients’
opinion on the efficacy of the topical rapamycin treatment of FFs
in BHD was measured, giving disparate results. Patients reported
improvement in some cases, whereas doctors observed no efficacy
of rapamycin treatment. All three doctors were blinded and they
evaluated the treatment twice at separate time points. Patients
were also blinded at the start of the treatment, but because side
effects occurred more often on the rapamycin treated side blinding
could have been compromised. Therefore patients might have
been biased towards experiencing improvement on the facial half
with most side effects. This can explain the difference in doctors’
and patients’ opinion on improvement of the FFs after treatment.
Most reported side effects were a sign of skin irritation.
Although these irritation signs occurred more often on the
rapamycin treated side, they were also reported on the placebo
treated side of the face. This suggests that the excipient, which
contains ethanol, may have been responsible for some of the side
effects.
In conclusion, we show that topical rapamycin as used by us is
not an effective treatment for FFs in BHD. It is still possible that a
higher concentration or oral administration could be effective.
However, very recent work provides evidence that reduced
expression of FLCN does not necessarily cause increased mTOR
activity. Thus, our present findings do not support further study of
rapamycin or similar compounds for the treatment of FF in BHD.
Development of an effective topical treatment will have to await
full elucidation of FLCN’s functions in cellular signalling.
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